Effect of intranigral dosage with delta-sleep-inducing peptide and its analogs on movement and convulsive activity in rats
- 19 Downloads
- 4 Citations
Abstract
Studies were carried out in rats on the effects of the administration of delta-sleep-inducing peptide (DSIP) and its analogs (1–4) into the reticular part of the substantia nigra on movement and convulsive activity. Intranigral microinjection of DSIP, and of DSIP-1 and DSIP-4, reduced horizontal and vertical movement activity as well as excursions to the center of the open field. DSIP, DSIP-2, and DSIP-3 had anticonvulsant effects, consisting of increases in the latent periods of the first convulsion and clonicotonic convulsions induced by picrotoxin, and reductions in the mean intensity of convulsions. It is suggested that changes in the structure of DSIP are accompanied by alterations in the strength of the effects of this peptide on horizontal and convulsive activity after dosage into the reticular part of the substantia nigra. The results indicating that these peptides have protective activity in experimental convulsive syndrome suggest that a relationship exists between DSIP-induced reductions in movement activity and the anticonvulsive efficacy of DSIP analogs when administered intranigrally, this being one of the components of the nigrodependent mechanisms of inhibition of convulsions.
Keywords
Peptide Open Field Latent Period Substantia Nigra Vertical MovementPreview
Unable to display preview. Download preview PDF.
References
- 1.O. S. Adrianov, N. S. Popova, E. L. Devedova, et al., “Delta-sleep-inducing peptide in experimental pathology,” Proceedings of the Second Conference on Neurosciences [in Russian], Kiev (1988), pp. 86–87.Google Scholar
- 2.Ya. Buresh, O. Bureshova, and D. Houston, Methods and Basic Experiments in Studies of the Brain and Behavior [in Russian], Moscow (1991).Google Scholar
- 3.G. N. Kryzhanovskii, A. A. Shandra, L. S. Godlevskii, et al., “The effect of delta-sleep-inducing peptide on epileptic activity in the cerebral cortex of rats and cats,” Byull. Éksp. Biol. Med.,104, No. 11, 582–585 (1987).Google Scholar
- 4.A. M. Mendzheritskii, N. I. Uskova, I. O. Chorayan, and I. I. Mikhileva, “The chronobiological effects of delta-sleep-inducing peptide and the GABA system in the rat brain,” Neirokhimiya,9, No. 2, 253–258 (1990).Google Scholar
- 5.D. Sepetliev, Statistical Methods in Scientific Medical Investigations [in Russian], Moscow (1968).Google Scholar
- 6.A. A. Shandra, L. S. Godlevskii, G. N. Kryzhanovskii, et al., “The effect of delta-sleep-inducing peptide on convulsive activity in corasol kindling,” Byull. Éksp. Biol. Med.,106, No. 9, 269–271 (1988).Google Scholar
- 7.A. A. Shandra, L. S. Godlevskii, A. M. Mazarati, and R. F. Makul'kin, “The effects of delta-sleep-inducing peptide, anticonvulsive preparations, and nicotinamide on generalized convulsive activity,” Byull. Éksp. Biol. Med.,107, No. 2, 211–214 (1989).Google Scholar
- 8.A. A. Shandra, L. S. Golevskii, A. M. Mazarati, and R. F. Makul'kin, “The role of the substantia nigra in the anticonvulsive and antiaggressive effects of diazepam in conditions of pharmacological kindling,” Neirofiziologiya,22, No. 4, 482–487 (1990).Google Scholar
- 9.J. A. Ball, “Diazepam binding inhibitor-like immunoreactivity (51–70): distribution in human brain, spinal cord and peripheral tissues,” Brain Res.,479, No. 2, 300–305 (1989).PubMedGoogle Scholar
- 10.K. Gale, “Role of substantia nigra in GABA-mediated anticonvulsant action,” in: Adv. In Neurol. Basic Mechanisms of the Epilepsies: Molecular and Cellular Approaches, A. V. Delgado-Escueta, et al. (eds.), New York (1986), Vol. 44, pp. 343–365.Google Scholar
- 11.D. S. Garant and K. Gale, “Intranigral muscimol attenuates electrographic signs of seizure activity induced by intravenous bicuculline in rats,” Eur. J. Pharmacol.,124, No. 2, 365–369 (1986).PubMedGoogle Scholar
- 12.L. Kapas, F. J. Obal, P. Alfordi, et al., “Effects of nocturnal intraperitoneal administration of cholecystokinin in rats: simultaneous increase in sleep, increase in EEG slow-wave activity, reduction of motor activity, suppression of eating and decrease of brain temperature,” Brain Res.,438, No. 1-2, 155–164 (1988).PubMedGoogle Scholar
- 13.P. H. King, C. Shin, H. H. Mansbach, et al., “Microinjection of benzodiazepine into substantia nigra elevated kindled seizure threshold,” Brain Res.,423, No. 1, 261–268 (1987).PubMedGoogle Scholar
- 14.G. N. Kryzhanovsky, A. A. Shandra, L. S. Godlevsky, and M. Y. Karganov, “Antiepileptic properties of cerebrospinal fluid after activation of the antiepileptic system of the brain,” Epilepsia,30, No. 5, 631–635 (1989).PubMedGoogle Scholar
- 15.K. Kuzuhiko, S. Kiminotu, M. Ikuko, et al., “Cholecystokinin antagonism by benzodiazepines: a new approach to the mechanisms of action of benzodiazepines,” J. Pharmcobiodynamics,9, No. 8, 100 (1986).Google Scholar
- 16.T. Hokfelt, M. Herrera-Marchita, K. Seroogy, et al., “Immunochemical studies on cholecystokinin (CCK)-immunoreactive neurons in the rat using sequence-specific antisera and with special reference to the caudate nucleus,” J. Chem. Neuroanatomy,1, No. 1, 11–52 (1988).Google Scholar
- 17.G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates, Sydney (1982).Google Scholar
- 18.A. A. Shandra, L. S. Godlevsky, A. M. Mazarati, et al., “Delta-sleep inducing peptide (DSIP)-dependent mechanisms of pharmacological kindling,” I Congress of Epileptology, Polish Chapter of the International League against Epilepsy, Warsaw (1991), p. 64.Google Scholar
- 19.A. A. Shandra, L. S. Godlevsky, A. M. Mazarati, and A. A. Lobenko, “Role of substantia nigra reticulata in anxiolytic and antiepileptic effects of diazepam,” Abstr. Of the 5th World Congress of Biological Psychiatry,29, No. 115, 49–55 (1991).Google Scholar
- 20.G. Zetler, “Anticonvulsant effects of caerulein and cholecystokinin octapeptide (CCK-8) and diazepam against seizure produced in mice by harman, thiosemicarbazide, and isoniazid,” Neurosci. Lett.,24, No. 2, 175–180 (1981).PubMedGoogle Scholar